The Pilot Study of DXA Assessment in Chinese HIV-Infected Men With Clinical Lipodystrophy

Journal of Clinical Densitometry

Volumn 14, Issue 1, 2011, Pages 58-62

  Yao, Jinpeng ^a   Yu, Wei ^a   Li, Taisheng ^a   Luo, Ling ^a   Lin, Qiang ^a   Tian, Junping ^a   Chang, Yinjuan ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Bone mineral content; Dual energy X ray absorptiometry (DXA); Fat mass; Lean mass; Lipodystrophy

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BONE DENSITY; BONE MINERAL; CHINESE; CLINICAL ARTICLE; DISEASE DURATION; DUAL ENERGY X RAY ABSORPTIOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MALE; PILOT STUDY; PRIORITY JOURNAL;

ABSORPTIOMETRY, PHOTON; ADIPOSE TISSUE; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASIAN CONTINENTAL ANCESTRY GROUP; BODY COMPOSITION; BODY WEIGHTS AND MEASURES; BONE DENSITY; BONE RESORPTION; HIV; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS;

EID: 79551472969     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocd.2010.08.002     Document Type: Article

References (25)

1. Robinson E.P. HIV lipodystrophy syndrome: a primer. JANAC 2004, 15:15-29.
2. Carr A., Samaras K., Burton S., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:f51-f58.
3. Montessori V., Press N., Harris M., et al. Adverse effects of antiretroviral therapy for HIV infection. CMAJ 2004, 170:229-238.
4. Lichtenstein K.A., Ward D.J., Moorman A.C., et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001, 15:1389-1398.
5. Tien P.C., Grunfeld C. What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection. AIDS 2004, 17:27-32.
6. Hadigan C., Meigs J., Corcoran C., et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001, 32:130-133.
7. Vander Valk M., Gisolf E.H., Reiss P., et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 2001, 15:847-855.
8. Cavalcanti R.B., Cheung A.M., Raboud J., et al. Reproducibility of DXA estimations of body fat in HIV lipodystrophy. J Clin Densitom 2005, 8:193-197.
9. Lu Z., Ming L., Mei mei T., et al. A study of HIV-related lipodystrophy syndrome in 55 HIV-infected Chinese adult patients. Chin J Intern Med 2009, 48:118-121.
10. FRAM Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005, 40:121-131.
11. Delpierre C., Bonnet E., Latard F.M., et al. Impact of HIV infection on total body composition in treatment-naïve men evaluated by dual-energy X-ray absorptiometry comparison of 90 untreated HIV-infected men to 241 controls. J Clin Densitom 2007, 10:376-380.
12. Scherzer R., Shen W., Baccetti P., et al. Comparison of dual-energy X-ray absorptiometry and magnetic resonance imaging-measured adipose tissue depots in HIV-infected and control subjects. Am J Clin Nutr 2008, 88:1088-1096.
13. FRAM Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr 2006, 42:562-571.
14. Chang K.H., Kim J.M., Song Y.G., et al. Does race protect an oriental population from developing lipodystrophy in HIV-infected individuals an HAART?. HIV/AIDS 2002, 44:33-48.
15. Mondy K., Overton E.T., Grubb J., et al. Metabolic syndrome in HIV-infected patients from an urban, Midwestern US outpatient population. HIV/AIDS 2007, 44:726-734.
16. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults. JAMA 2002, 287:356-359.
17. Kotler D.P. HIV infection and lipodystrophy. Prog Cardiovasc Dis 2003, 45:169-284.
18. Galli M., Veglia F., Angarano G., et al. Gender differences in antiretroviral drug-related adipose tissue alterations. J Acquir Immune Defic Syndr 2003, 34:58-61.
19. Kulk J.L., Saunders T.J., Davidson L.E., et al. Age-related changes in total and regional fat distribution. Ageing Res Rev 2009, 8:339-348.
20. Reid I.R. Relationships among body mass, its components and bone. Bone 2002, 31:547-555.
21. McDermott A.Y., Shevitz A., Knox T., et al. Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women. Am J Clin Nutr 2001, 74:679-686.
22. Rosenthall L., Falutz J. Bone mineral and soft-tissue changes in AIDS-associated lipoatrophy. J Bone Miner Metab 2005, 23:53-57.
23. Borderi M., Gibellini D., Vescini F., et al. Metabolic bone disease in HIV infection. AIDS 2009, 23:1297-1310.
24. Gavrila A., Tsiodras S., Dowerko J., et al. Exercise and vitamin E intake are independently associated with metabolic abnormalities in human immunodeficiency virus-positive subjects: a cross-sectional study. HIV/AIDS 2003, 36:1593-1601.
25. Wanke C., Kotler D. The approach to diagnosis and treatment of HIV wasting. Acquir Immune Defic Syndr 2004, 37(Suppl 5):S284-S288. and the HIV wasting collaborative consensus committee.